Mitochondrial fatty acid ?-oxidation is traditionally viewed as an energy-generating, catabolic pathway but intermediates of this pathway can serve as key substrates for synthesis of other complex lipids. The long range objective of this project is to define the role of fatty acid oxidaton proteins in intermediary metabolism and the clinical impact of their deficiency due to inborn errors. The goal of the first funding period was to characterize the functional roles of LCAD, VLCAD, and ACAD9 and to explore the ramifications of genetic deficiencies of these enzymes in humans and mouse models. Significant progress has been made on each of these aims. Our chief findings include the ground breaking identification and partial purification of a multifunctional fatty acid oxidation complex containing all of the activities of this pathway in association with the mitochondrial respiratory chain super complexes and identification of the first patient with LCAD deficiency, presenting as predicted with a surfactant deficiency. The goal of this renewal application is to examine the expanding role of long chain fatty acid oxidation in normal metabolism and disease. It has three specific aims.
Specific Aim 1 is to characterize the structure of the multifunctional fatty acid oxidation complex and its interaction with the mitochondrial respiratory chain. I hypothesize that this contact is critical to the channeling of reducing equivalents from fatty acid oxidation to the respiratory chain and that disruption of this process reduces the efficiency of mitochondrial energy generation.
Specific Aim 1 a is to elucidate the mechanism of electron transfer by first deducing the structure of the multifunctional FAOD complex using cryoelectron microscopy.
Specific Aim 1 b is to examine the role of patient identified mutations on VLCAD function, including their effect on the integrity of the FAOD multifunctional complex.
Specific Aim 1 c is to characterize the integrity of the fatty acid oxidatin complex in VLCAD and LCAD deficient mouse models.
Specific Aim 2 is to characterize the disparate effects of null and point mutations in the ACAD9 gene on protein structure and function. I hypothesize that ACAD9 serves a duel function in mitochondria as a metabolic enzyme and a respiratory chain assembly/stability factor.
Specific Aim 2 a is to examine the metabolic and moonlighting functions of ACAD9 in cells from deficient human patients.
Specific Aim 2 b is to characterize the range of biochemical and clinical effects in an ACAD9 knock out mouse model.
Specific Aim 3 is to further characterize LCAD deficiency in patients and a knock out mouse model, and to elucidate its function in surfactant metabolism.
Specific Aim 3 a is to examine surfactant metabolism in wild type and LCAD deficient primary pneumocytes.
Specific Aim 3 b is to characterize the incidence and spectrum of clinical symptoms in LCAD deficiency.

Public Health Relevance

The acyl-CoA dehydrogenases are important enzymes in maintaining normal chemical balance in the body. We have identified two new genetic disorder of one of these enzymes that leads to liver failure and lung disease. Studying these disorders is important to learn more about their clinical presentation and treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK078775-06
Application #
8485595
Study Section
Therapeutic Approaches to Genetic Diseases (TAG)
Program Officer
Mckeon, Catherine T
Project Start
2007-07-01
Project End
2016-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
6
Fiscal Year
2013
Total Cost
$313,656
Indirect Cost
$103,768
Name
University of Pittsburgh
Department
Pediatrics
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Pena, Loren D M; van Calcar, Sandra C; Hansen, Joyanna et al. (2016) Outcomes and genotype-phenotype correlations in 52 individuals with VLCAD deficiency diagnosed by NBS and enrolled in the IBEM-IS database. Mol Genet Metab 118:272-81
Staufner, Christian; Haack, Tobias B; Köpke, Marlies G et al. (2016) Recurrent acute liver failure due to NBAS deficiency: phenotypic spectrum, disease mechanisms, and therapeutic concepts. J Inherit Metab Dis 39:3-16
Vockley, J; Charrow, J; Ganesh, J et al. (2016) Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders. Mol Genet Metab 119:223-231
Prabhu, Dolly; Goldstein, Amy C; El-Khoury, Riyad et al. (2015) ANT2-defective fibroblasts exhibit normal mitochondrial bioenergetics. Mol Genet Metab Rep 3:43-46
Vockley, Jerry; Marsden, Deborah; McCracken, Elizabeth et al. (2015) Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment--A retrospective chart review. Mol Genet Metab 116:53-60
Odle, Jack; Adams, Sean H; Vockley, Jerry (2014) Carnitine. Adv Nutr 5:289-90
Goetzman, Eric S; Alcorn, John F; Bharathi, Sivakama S et al. (2014) Long-chain acyl-CoA dehydrogenase deficiency as a cause of pulmonary surfactant dysfunction. J Biol Chem 289:10668-79
Chaly, Yury; Fu, Yu; Marinov, Anthony et al. (2014) Follistatin-like protein 1 enhances NLRP3 inflammasome-mediated IL-1β secretion from monocytes and macrophages. Eur J Immunol 44:1467-79
Edmunds, Lia R; Sharma, Lokendra; Kang, Audry et al. (2014) c-Myc programs fatty acid metabolism and dictates acetyl-CoA abundance and fate. J Biol Chem 289:25382-92
Bharathi, Sivakama S; Zhang, Yuxun; Mohsen, Al-Walid et al. (2013) Sirtuin 3 (SIRT3) protein regulates long-chain acyl-CoA dehydrogenase by deacetylating conserved lysines near the active site. J Biol Chem 288:33837-47

Showing the most recent 10 out of 27 publications